Prahlad Singh

Prahlad Singh serves as President and CEO of Revvity, formerly PerkinElmer — a transformation that involved not just a name change but a fundamental reshaping of the company's identity. In 2023, PerkinElmer divested its analytical instruments and enterprise services business to New Mountain Capital for $2.45 billion and rebranded the remaining life sciences and diagnostics business as Revvity. Revvity operates in two segments: Life Sciences (reagents, instruments, and software for drug discovery, genomics research, and cell analysis) and Diagnostics (newborn screening, prenatal screening, immunodiagnostics, and applied genomics). The company holds a dominant global position in newborn screening — testing newborns for metabolic and genetic disorders — with the broadest menu of screening tests and the largest installed base of screening instruments worldwide. The diagnostics business provides stability through recurring revenue from reagent sales, while the life sciences business offers growth exposure to pharmaceutical R&D spending and genomics adoption. Revvity has been investing in next-generation platforms for gene therapy development, CRISPR-based editing tools, and high-content imaging systems. Key stock drivers include pharmaceutical R&D spending trends, newborn screening program expansions in developing countries, genetic testing adoption, post-COVID diagnostic revenue normalization, and the success of new product launches.